Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Belite Bio Inc BLTE

Healthcare Biotechnology
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as atrophic age-related macular degeneration (AMD), and autosomal recessive Stargardt disease type 1 (STGD) both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic... see more

Recent & Breaking News (NDAQ:BLTE)

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

GlobeNewswire November 27, 2024

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire November 12, 2024

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

GlobeNewswire November 5, 2024

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

GlobeNewswire November 3, 2024

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

GlobeNewswire October 14, 2024

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

GlobeNewswire October 8, 2024

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

GlobeNewswire September 10, 2024

Belite Bio to Participate in Three Upcoming Investor Conferences

GlobeNewswire September 3, 2024

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

GlobeNewswire September 1, 2024

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire August 9, 2024

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire August 8, 2024

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

GlobeNewswire August 5, 2024

Belite Bio to Present at the JonesHealthcare Seaside Summit

GlobeNewswire July 8, 2024

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

GlobeNewswire June 12, 2024

Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference

GlobeNewswire May 14, 2024

Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2024

Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

GlobeNewswire May 13, 2024

Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results

GlobeNewswire May 8, 2024

Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant

GlobeNewswire May 6, 2024

Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting

GlobeNewswire May 6, 2024